The World Health Organization (WHO) designated the JN.1 coronavirus strain as a “variant of interest” and indicated that, based on current evidence, the risk to public health from this strain is low. Despite its ability to evade the immune system and exhibit higher transmissibility compared to other circulating variants. Experts assert that JN.1 does not show any signs of causing more severe disease.

While there may be an increase in cases involving the JN.1 variant, it is emphasized that it does not pose a greater risk. JN.1, initially considered a variant of interest within the BA.2.86 lineage, has now been classified separately by the WHO.

The World Health Organization assured that existing vaccines remain effective in protecting against severe disease and death caused by JN.1 and other variants of the COVID-19 virus currently in circulation.

According to the U.S. Centers for Disease Control and Prevention (CDC), as of December 8, the JN.1 subvariant constitutes an estimated 15% to 29% of cases in the United States. The CDC maintains that there is no current evidence suggesting an elevated risk to public health compared to other circulating variants. Additionally, it is stated that an updated vaccine could provide continued protection against the JN.1 variant.

First detected in the United States in September, JN.1 has also been identified in seven cases in China, as reported last week.

The medical information on this site is provided as an information resource only and is not to be used or relied on for any diagnostic or treatment purposes. This information does not substitute for professional diagnosis and treatment. Please do not initiate, modify, or discontinue any treatment, medication, or supplement solely based on this information. Always seek the advice of your health care provider first. Full Disclaimer: https://centrumpharmacy.com/disclaimer/